Novo Nordisk Seen Readying Steps To Offset US Pressures, Including Job Cuts
Executive Summary
Novo Nordisk is rumored to be considering laying off up to 3,000 staff and dropping its long-term financial targets due to challenging US market conditions which the group flagged in its first-quarter update in May.
You may also be interested in...
Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration
Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and more nimble. Headcount rationalization in R&D is rumored to be already underway, while more operational areas could potentially see significant manpower reductions.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.